Trial Information: A Phase I trial recruiting patients with all types of B-cell non-Hodgkin's lymphoma, including follicular lymphoma. Patients will be randomized to receive varying dosages of inotuzumab ozogamicin with rituximab, cyclophosphamide, vincristine and prednisone (R-CVP), or with rituximab, gemcitabine, dexamethasone, and cisplatinum (R-GDP). Open only to people with relapsed disease.
Background Information: Inotuzumab ozogamicine is a potentially powerful new anti-CD22 monoclonal antibody, targeting a surface protein different than of rituximab and related anti-CD20 monoclonal antibodies.
In early trials, inotuzumab showed particular promise in follicular lymphoma patients. A Japanese Phase I trial of 13 follicular lymphoma patients produced a response in 11 patients (85%), with 7 patients (54%) achieving complete remission. The new trial evaluates inotuzumab as part of combination therapy, where results may be even more striking.
Canadian Locations: Edmonton, AB; Halifax, NS; Quebec City, QC.
For more information, see ClinicalTrials.gov.
No comments:
Post a Comment